• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

首例伴有 ALK I1171N 突变的转移性 ALK 重排肺癌患者使用恩沙替尼治疗的病例报告

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.

机构信息

Department of Head, Neck and Thoracic Oncology, First People's Hospital of Foshan, Foshan, China.

出版信息

World J Surg Oncol. 2023 Mar 2;21(1):74. doi: 10.1186/s12957-023-02935-9.

DOI:10.1186/s12957-023-02935-9
PMID:36864442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9979531/
Abstract

BACKGROUND

The acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance.

CASE PRESENTATION

Here, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months.

CONCLUSIONS

This treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20.

摘要

背景

ALK 酪氨酸激酶抑制剂（TKIs）获得性耐药与 ALK 重排 NSCLC 的不良生存结局相关，并带来了明显的临床挑战。因此，开发克服耐药的潜在治疗策略至关重要。

病例介绍

在此，我们首次报道了一例接受恩沙替尼治疗的获得性 ALK 耐药突变（ALK 11171N）的女性肺腺癌患者。她在仅接受 20 天治疗后症状显著改善，且仅有轻度皮疹的副作用。3 个月后随访图像观察到无进一步脑转移。

结论

这种治疗方法可能为 ALK TKI 耐药患者提供新的治疗策略，特别是在 ALK 外显子 20 的 1171 位置。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1342/9979531/b84a79a927fb/12957_2023_2935_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1342/9979531/6f4dd6804f45/12957_2023_2935_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1342/9979531/b84a79a927fb/12957_2023_2935_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1342/9979531/6f4dd6804f45/12957_2023_2935_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1342/9979531/b84a79a927fb/12957_2023_2935_Fig2_HTML.jpg

相似文献

1
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.首例伴有 ALK I1171N 突变的转移性 ALK 重排肺癌患者使用恩沙替尼治疗的病例报告
World J Surg Oncol. 2023 Mar 2;21(1):74. doi: 10.1186/s12957-023-02935-9.
2
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.I1171错义突变（尤其是I1171N）是在接受阿来替尼治疗时病情进展且对色瑞替尼敏感的ALK阳性非小细胞肺癌患者中常见的耐药突变。
Lung Cancer. 2015 May;88(2):231-4. doi: 10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12.
3
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
4
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.监测治疗反应和耐药性：ALK+肺癌患者循环肿瘤 DNA 分析。
J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003. Epub 2019 Aug 22.
5
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.在对阿来替尼耐药的两个存在 ALK 重排的非小细胞肺癌（NSCLC）患者中发现了一种新型的 HIP1-ALK 融合变体和 ALK I1171（I1171N/S）突变。
J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
6
Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report.获得性ALK G1202R、ALK I1171N或EML4-ALK介导的肺腺癌对恩沙替尼耐药但对劳拉替尼敏感：一例报告。
Front Oncol. 2023 Mar 16;13:1082115. doi: 10.3389/fonc.2023.1082115. eCollection 2023.
7
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.恩沙替尼（X-396）治疗间变性淋巴瘤激酶阳性非小细胞肺癌：一项多中心、I/II 期首次人体研究结果。
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.
8
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.在ALK阳性非小细胞肺癌肿瘤样本和循环肿瘤DNA中鉴定I1171N耐药突变。
Lung Cancer. 2016 Sep;99:38-40. doi: 10.1016/j.lungcan.2016.06.010. Epub 2016 Jun 14.
9
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.恩沙替尼治疗克唑替尼耐药、ALK 阳性非小细胞肺癌的疗效、安全性和生物标志物分析：一项多中心、Ⅱ期临床试验。
Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15.
10
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.ALK重排的晚期非小细胞肺癌（NSCLC）对克唑替尼的耐药性：机制、治疗策略及新的靶向治疗方法
Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134.

引用本文的文献

1
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report.恩沙替尼治疗伴有TP53、EGFR和ERBB2共突变的EML4-ALK阳性肺腺癌：一例报告
Front Oncol. 2025 Feb 14;15:1520287. doi: 10.3389/fonc.2025.1520287. eCollection 2025.
2
A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review.一种对第二代酪氨酸激酶抑制剂耐药的新型间变性淋巴瘤激酶（ALK）基因二次突变：病例报告及文献综述
Front Oncol. 2024 Aug 29;14:1430350. doi: 10.3389/fonc.2024.1430350. eCollection 2024.
3
Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.

本文引用的文献

1
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.恩沙替尼对比克唑替尼用于间变性淋巴瘤激酶阳性非小细胞肺癌患者：一项随机临床试验。
JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523.
2
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.恩沙替尼治疗克唑替尼耐药、ALK 阳性非小细胞肺癌的疗效、安全性和生物标志物分析：一项多中心、Ⅱ期临床试验。
Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15.
3
病例报告：恩莎替尼治疗伴有STRN-ALK融合的胃上皮样炎性肌纤维母细胞瘤
Front Oncol. 2023 Oct 5;13:1252221. doi: 10.3389/fonc.2023.1252221. eCollection 2023.
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
监测治疗反应和耐药性：ALK+肺癌患者循环肿瘤 DNA 分析。
J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003. Epub 2019 Aug 22.
4
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.恩沙替尼（X-396）治疗间变性淋巴瘤激酶阳性非小细胞肺癌：一项多中心、I/II 期首次人体研究结果。
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.
5
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.ALK 重排肺癌对第一代和第二代 ALK 抑制剂耐药的分子机制
Cancer Discov. 2016 Oct;6(10):1118-1133. doi: 10.1158/2159-8290.CD-16-0596. Epub 2016 Jul 18.
6
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.阿来替尼用于ALK阳性、克唑替尼耐药的非小细胞肺癌：一项单组、多中心、2期试验。
Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19.
7
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
8
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.通过新型 ALK 酪氨酸激酶抑制剂的开发揭示 ALK 驱动型癌症的见解。
Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25.